FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 06/2024”. The Monitor is a month-to-month printed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the top of June 2024 we establish the next present VC traits in Europe:
-
Whole Healthcare & Life Sciences funding reached EUR 4,110m.
-
Biotech obtained 59% of the overall funding quantity (EUR 2,439m) with oncology being the main indication (50%).
-
In June, Vivid Peak Therapeutics (Switzerland) secures the best transaction quantity with EUR 83m, adopted by iOnctura (Switzerland) with EUR 80m and UroMems (France) with EUR 44m.
-
European Innovation Council Fund (Belgium) is essentially the most energetic investor (by deal quantity), adopted by M&G Investments (United Kingdom) and Affected person Sq. Capital (United States).
To entry the complete report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink